Not Yet Recruiting OBSERVATIONAL NCT07448402
Costa Rican Registry of IL-23 Inhibitors in Psoriatic Disease
National Registry of Patients With Psoriatic Disease Receiving Interleukin-23 Inhibitor Therapy Within the Costa Rican Social Security System
Sponsor: Caja Costarricense de Seguro Social
Conditions
Psoriasis Psoriasis (PsO) Psoriasis Arthritis
Interventions
Guselkumab (GUS) Risankizumab (RISA)
Updated 1 time since 2026 Last updated: Mar 6, 2026 Started: May 31, 2026 Primary completion: May 31, 2031 Completion: May 31, 2031
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
Listed as NCT07448402, this observational or N/A phase trial focuses on Psoriasis and Psoriasis (PsO) and remains actively recruiting participants. Sponsored by Caja Costarricense de Seguro Social, it has been updated 1 time since 2026, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
1 version recorded Not Yet Recruiting
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Caja Costarricense de Seguro Social
Data source: Caja Costarricense de Seguro Social
For direct contact, visit the study record on ClinicalTrials.gov .